# US 2009/0263431 A1 · Polyurethane foams for wound management

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0263431 A1
- Document ID: US20090263431A1
- Status: Published application
- Kind: A1
- Application number: 12/244,313
- Filed: 2008-10-02
- Published: 2009-10-22
- Earliest claimed: 2007-10-05
- Assignees: Bayer Innovation GmbH
- Inventors: Burkhard Fugmann; Melita Dietze; Thorsten Rische; Michael Mager; Michael Heckes; Daniel Rudhardt; Rolf Gertzmann; Jan Schonberger; Sebastian Dorr
- Web page: https://patentgrep.com/patent/US20090263431A1

## CPC

- C08J 9/0004: {Use of compounding ingredients, the chemical constitution of which is unknown, broadly defined, or irrelevant}
- A61L 15/225: {Mixtures of macromolecular compounds}
- A61L 15/425: {Porous materials, e.g. foams or sponges}
- C08J 2375/04: Polyurethanes
- C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The invention relates to a process for producing polyurethane foams for wound management wherein a composition containing a polyurethane dispersion and specific coagulants is frothed and dried.

## Claims

### Claim 1

A process for producing wound contact materials made of polyurethane foams which comprises a composition containing an aqueous, anionically hydrophilicized polyurethane dispersion (I), a cationic coagulant (II) and additionally at least one active component selected from the group consisting of antiseptics, growth factors, protease inhibitors and non-steroidal anti-inflammatories/opiates being frothed and dried.

### Claim 2 (depends on 1)

A process according to claim 1, wherein the aqueous, anionically hydrophilicized polyurethane dispersions (I) are obtainable by
A) isocyanate-functional prepolymers being produced from
A1) organic polyisocyanates
A2) polymeric polyols having number-average molecular weights in the range from 400 to 8000 g/mol and OH functionalities in the range from 1.5 to 6 and
A3) optionally hydroxyl-functional compounds having molecular weights in the range from 62 to 399 g/mol and
A4) optionally isocyanate-reactive, anionic or potentially anionic and optionally nonionic hydrophilicizing agents
and
B) their free NCO groups then being wholly or partly reacted
B1) optionally with amino-functional compounds having molecular weights in the range from 32 to 400 g/mol and
B2) with amino-functional, anionic or potentially anionic hydrophilicizing agents by chain extension, and the prepolymers being dispersed in water before, during or after step B), any potentially ionic groups present being converted into the ionic form by partial or complete reaction with a neutralizing agent.

### Claim 3 (depends on 2)

A process according to claim 2, wherein the aqueous, anionically hydrophilicized polyurethane dispersions (I) are produced using in A1) 1,6-hexamethylene diisocyanate, isophorone diisocyanate, the isomeric bis-(4,4′-isocyanatocyclohexyl)methanes and also mixtures thereof and in A2) a mixture of polycarbonate polyols and polytetramethylene glycol polyols, the proportion of component A2) which is contributed by the sum total of the polycarbonate and polytetramethylene glycol polyether polyols being at least 70% by weight.

### Claim 4 (depends on 1)

A process according to claim 1, wherein the cationic coagulant (II) is an acrylamide copolymer comprising structural units of the general formula (1) and (2)
where
R is C═O, —COO(CH2)2— or —COO(CH2)3— and
X− is a halide ion.

### Claim 5 (depends on 1)

A process according to claim 1, wherein the auxiliary and additive materials (III) are included as well as the polyurethane dispersion (I) and the cationic coagulant (II).

### Claim 6 (depends on 5)

A process according to claim 5, wherein as auxiliary and additive materials (III) there are included fatty acid amides, sulphosuccinamides, hydrocarbyl sulphonates or sulphates, fatty acid salts and/or alkylpolyglycosides as foam formers and stabilizers.

### Claim 7 (depends on 6)

A process according to claim 6, wherein the mixtures of sulphosuccinamides and ammonium stearates are used as foam formers and stabilizers, these mixtures containing 70% to 50% by weight of sulphosuccinamides.

### Claim 8 (depends on 1)

A process according to claim 1, wherein the active component comprises an antiseptic biguanide.

### Claim 9 (depends on 8)

A process according to claim 8, wherein the antiseptic biguanide is poly(hexamethylene)biguanide (PHMB).

### Claim 10 (depends on 1)

Wound contact materials obtainable by a process according to claim 1.

### Claim 11 (depends on 10)

Wound contact materials according to claim 10, wherein they have a microporous, open-cell structure and a density of below 0.4 g/cm3 in the dried state.

### Claim 12 (depends on 10)

Wound contact materials according to claim 10, wherein they have a DIN EN 13726-1 Part 3.2 physiological saline absorbency in the range from 100 to 1500% (mass of liquid taken up, based on the mass of dry foam) and a DIN EN 13726-2 Part 3.2 water vapour transmission rate in the range from 2000 to 8000 g/24 h*m2.

### Claim 13

A composition containing an aqueous, anionically hydrophilicized polyurethane dispersion (I), a cationic coagulant (II) and additionally at least one active component selected from the group consisting of antiseptics, growth factors, protease inhibitors and non-steroidal anti-inflammatories/opiates.

### Claim 14 (depends on 13)

A composition according to claim 13, wherein the active component comprises an antiseptic biguanide.

### Claim 15 (depends on 14)

A composition according to claim 14, wherein the antiseptic biguanide is poly(hexamethylene)biguanide (PHMB).
